Convalife (shanghai) Co., Ltd.
Clinical trials sponsored by Convalife (shanghai) Co., Ltd., explained in plain language.
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors or slow their g…
Phase: PHASE1, PHASE2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 12:11 UTC
-
New pill-and-shot combo targets hard-to-treat cancers with PTEN loss
Disease control Not yet recruitingThis study tests a new combination of two drugs (CVL237 tablets and serplulimab injection) in people with advanced solid tumors that have lost or have low levels of a protein called PTEN. The goal is to see if the combo can shrink or control the cancer. About 180 adults aged 18-7…
Phase: PHASE2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 12:08 UTC